A position paper was published yesterday by the European Heart Rhythm Association reporting on the performance of new devices for the treatment of heart failure (HF). The report has been endorsed by the Heart Failure Association. The abstract for the paper titled “New devices in heart failure: an European Heart Rhythm Association report” reads:
CVRx was founded in Minneapolis, MN in 2001 by Dr. Robert Kieval to develop an implantable system for the treatment of hypertension. CVRx’s implantable pulse generators deliver stimulation to the baroeceptors in the carotid arteries to induce a baroreflex that causes a drop in blood pressure in patients with refractory hypertension.